TITLE

β-Tubulin III mRNA expression and docetaxel sensitivity in non-small cell lung cancer

AUTHOR(S)
Li-feng Wang; Hai-tao Yin; Xiao-ping Qian; Jia Wei; Yang Zhao; Li-xia Yu; Bao-rui Liu
PUB. DATE
December 2009
SOURCE
Clinical & Investigative Medicine;Dec2009, Vol. 32 Issue 6, pE278
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: Despite the success of docetaxel as an antitumour agent, the inter-individual variability in drug response still poses a major impediment to further use of this agent in the treatment of cancer. Current knowledge about predictive biomarkers of docetaxel sensitivity in malignant effusions is poor. The aim of this study was to investigate the association between β-tubulin III mRNA expression and chemosensitivity to docetaxel in metastatic malignant effusions. Methods: Real-time quantitative PCR was used for analysis of β-tubulin III mRNA expression in 37 malignant effusions collected prospectively. Viable tumour cells obtained from malignant effusions were tested for sensitivity to docetaxel using ATP-TCA assay. Results: β-tubulin III expression was inversely correlated with sensitivity to docetaxel in pleural effusions of NSCLC patients (P =0.022). The lower level of β-tubulin III mRNA expression in malignant effusions was associated with higher chemosensitivity to docetaxel in NSCLC patients in vitro. No correlation was found between β-tubulin III mRNA expression and docetaxel sensitivity in malignant effusions of gastric cancer patient. Conclusion: Our results demonstrated that β-tubulin III mRNA expression level in malignant effusions, in which all cancer cells were metastatic, was correlated with docetaxel sensitivity in NSCLC. This highlights the potential role of biomarkers in malignant effusions in further customized chemotherapy.
ACCESSION #
47781875

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics